Need professional-grade analysis? Visit stockanalysis.com
$2.12B
N/A
188
N/A
Avadel Pharmaceuticals PLC (AVDL) trades on United States in USD. The company is classified in the Healthcare sector under the Drug Manufacturers - Specialty & Generic industry. The stock currently trades at $21.64, up 0.05% from the previous close.
Over the past year, AVDL has traded between a low of $8.27 and a high of $23.56. The stock has gained 161.7% over this period. It is currently 8.1% below its 52-week high.
Avadel Pharmaceuticals PLC has a market capitalization of $2.12B.
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is the LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of cataplexy or excessive daytime sleepiness in patients seven years of age and older with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin 2, Ireland. As of February 12, 2026, Avadel Pharmaceuticals plc operates as a subsidiary of Alkermes plc.
Side-by-side comparison against top Healthcare peers.